Palliative management of hepatocarc inoma with sorafenib (nexavar®). Results of the sharp study (sorafenib hepatocarcinoma assessment randomized protocol trial);L'étude clinique du mois traitement de l'hépatocarcinome au stade palliatif par sorafénib (nexavar®) résultats de l'étude sharp (sorafenib hepatocarcinoma assessment randomized protocol)

Revue Medicale de Liege

Volumn 64, Issue 3, 2009, Pages 168-170

  Detry, O ^a,b   Delwaide, J ^a   De Roover, A ^b   Meunier, P ^b   Van Daele, D ^b   Lamproye, A ^b   Honore, P ^a   Polus, M ^b  

^a Clinique

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Hepatocarcinoma; Liver; Oncology; Transplantation

Indexed keywords

PLACEBO; SORAFENIB;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; DRUG COST; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; RADIOFREQUENCY ABLATION; SHORT SURVEY; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR CELL; TUMOR NECROSIS;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PALLIATIVE CARE; PYRIDINES;

EID: 63849097160     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. 1.Parkin DM, Bray F, Ferlay J, Pisani P.-Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55, 74-108.
2. Llovet JM, Burroughs A, Bruix J.-Hepatocellular carcinoma. Lancet, 2003, 362, 1907-1917.
3. Bruix J, Sherman M.-Management of hepatocellular carcinoma. Hepatology, 2005, 42, 1208-1236.
4. Bruix J, Sherman M, Llovet JM, et al.-Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol, 2001, 35, 421-430.
5. Adnane L, Trail PA, Taylor I, Wilhelm SM.-Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/ MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/ PDGFR in tumor vasculature. Methods Enzymol, 2005, 407, 597-612.
6. Escudier BE, Eisen T, Stadler WM, et al.-Sorafénib in Advanced Clear-Cell Renal-Cell. Carcinoma N Engl J Med, 2007, 356, 125-134.
7. Abou-Alfa GK, Schwartz L, Ricci S, et al.-Phase II study of sorafénib in patients with Advanced hepatocellular carcinoma. J Clin Oncol, 2006, 24, 4293-4300.
8. Llovet JM, Ricci S, Mazzaferro V, et al.-Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359, 378-390.
9. Van Daele D, Belaiche J, Delwaide J, et al.-Traitement des carcinomes hépatocellulaires à un stade intermediare ou avancé. Rev Med Liege, 2009, 64, 140-147.
10. Roberts LR.-Sorafénib in liver cancer. Just the beginning. N Engl J Med, 2008, 359, 420-422.